Clinical Trial Update: A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641) [Phase 2]

View source ↗

Summary

A terminated Phase 2 open-label study evaluating 1% azithromycin ophthalmic solution (P08641) for posterior blepharoconjunctivitis. No results are provided in t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posterior Blepharoconjunctivitis

Drugs mentioned

• Azithromycin ophthalmic solution 1% (azithromycin ophthalmic solution)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Posterior Blepharoconjunctivitis | Phase 2 | Status: TERMINATED